Paper
Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia
Published 2005 · R. Silver
Leukemia
Q1 SJR score
17
Citations
0
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Non-RCTStudy Snapshot
Anagrelide effectively treats hydroxyurea-resistant thrombocytosis in chronic myeloid leukemia patients, potentially preventing thrombohemorrhagic complications.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Full text analysis coming soon...
References
Chronic myeloid leukemia.
Recent advances in cell biology and molecular genetics have yielded new data on chronic myeloid leukemia, with marrow transplantation and recombinant interferon playing significant clinical roles.
1992·1195citations·R. Silver et al.·The American journal of medicine
The American journal of medicine
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders
Imatinib mesylate and anagrelide combination therapy is safe and associated with an 89% complete hematologic response rate in patients with chronic phase CML and persistent thrombocythemia.
2003·10citations·A. Tsimberidou et al.·Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
Imatinib is superior to interferon alfa plus low-dose cytarabine as first-line therapy for newly diagnosed chronic-phase CML in terms of hematologic and cytogenetic responses, tolerability, and progression risk.
2003·3543citations·S. O’Brien et al.·The New England journal of medicine
The New England journal of medicine
Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count.
Anagrelide is a useful therapeutic adjunct for controlling thrombocytosis in chronic myelogenous leukemia patients with high platelet counts, reducing thrombohemorrhagic complications.
1998·27citations·O. Trapp et al.·Blood cells, molecules & diseases
Blood cells, molecules & diseases
Microvascular Disturbances, Thrombosis, and Bleeding in Thrombocythemia: Current Concepts and Perspectives
Hemostatic complications in thrombocythemia patients are caused by platelet-vessel wall abnormalities, and newer treatments like interferon-alpha and anagrelide show promise, but more controlled clinical trials are needed.
1997·34citations·F. Ravandi-Kashani et al.·Seminars in Thrombosis and Hemostasis
Seminars in Thrombosis and Hemostasis
Citations
Is very high platelet count always associated with essential thrombocythemia? An unusual presentation in a child.
A rare child with a very high platelet count has coexisted with both Philadelphia chromosome-positive and JAK2V617F mutations in chronic myeloid leukemia, challenging the clinical presentation, laboratory findings, and management.
2023·0citations·E. Aktekin et al.·Laboratory medicine
Laboratory medicine
Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/day
A low starting dose of anagrelide (0.5 mg/day) may result in fewer adverse events and lower discontinuation rates while providing comparable platelet-lowering effects in patients with essential thrombocythemia.
2020·4citations·Yoshinori Hashimoto et al.·International Journal of Hematology
International Journal of Hematology
PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth.
Anagrelide selectively inhibits cancer cell growth by interacting with PDE3A and SLFN12, causing cell cycle arrest and apoptosis, and reveals PDE3A and SLFN12 as potential targets for developing novel anti-cancer therapies.
2019·16citations·R. An et al.·American journal of cancer research
American journal of cancer research
Leukemia and Risk of Venous Thromboembolism: A Meta-analysis and Systematic Review of 144 Studies Comprising 162,126 Patients
The overall incidence of venous thromboembolism in leukemia patients is high, particularly in transplant recipients, and prophylactic approaches could significantly decrease this risk.
2017·23citations·Ying Wu et al.·Scientific Reports
Scientific Reports
Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide
Anagrelide is a well-tolerated alternative therapy for patients with essential thrombocythemia intolerant or resistant to hydroxyurea, with mild cardiac side effects that are easily manageable.
2015·0citations·M. Antelo et al.·Expert Review of Hematology
Expert Review of Hematology
Hydroxycarbamide: a user’s guide for chronic myeloproliferative disorders
Hydroxycarbamide is an effective treatment for chronic myeloproliferative disorders, but its potential for leukemic transformation remains controversial.
2011·84citations·J. Spivak et al.·Expert Review of Anticancer Therapy
Expert Review of Anticancer Therapy
Anagrelide: 20 years later
Anagrelide is a first-line drug for reducing platelet count in patients with thrombocytosis associated with chronic myeloproliferative disorders, but long-term safety and effectiveness require further monitoring.
2009·23citations·A. Emadi et al.·Expert Review of Anticancer Therapy
Expert Review of Anticancer Therapy
Comparison of population based metaheuristics for feature selection: Application to microarray data classification
PSOSVM, a particle swarm optimization algorithm with support vector machines, outperforms other methods in finding informative genes in microarray data classification, identifying potential cancer genes.
2008·69citations·El-Ghazali Talbi et al.·2008 IEEE/ACS International Conference on Computer Systems and Applications
2008 IEEE/ACS International Conference on Computer Systems and Applications